Efstathios Kastritis, MD, on Main Takeaways From Trial Examining Daratumumab Plus VCd to Treat AL Amyloidosis

Video
Conference|ASCO Annual Meeting: Hematology

Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.

CancerNetwork® had the opportunity to speak with Efstathios Kastritis, MD, at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting. The professor of medical oncology at the National and Kapodistrian University of Athens, in Athens, Greece, detailed the overall takeaway of the phase 3 ANDROMEDA trial (NCT03201965), specifically how treatment with daratumumab (Darzalex) plus bortezomib, cyclophosphamide, and dexamethasone (VCd) improved outcomes for patients with newly diagnosed light chain (AL) amyloidosis.

Transcription:

We do have a very effective and relatively safe therapy for patients with AL amyloidosis, which has really and substantially improved the outcomes of our patients, [with] both complete hematologic response rates and organ responses, which is actually the ultimate goal of therapy in these patients. I really expect that this will be translated in an improvement in the overall survival in the follow up of this study.

Reference

Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Virtual. Abstract 8003.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.
Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.
Related Content
Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

Data Show Barriers to Immunotherapy Access in Clear Cell RCC Population

December 1st 2023
Article

Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023

August 7th 2023
Podcast

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD.

Durvalumab/Tremelimumab/Surgery Appears Safe in Renal Cell Carcinoma

November 30th 2023
Article

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer

Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer

November 26th 2023
Article

Significant progression-free survival was seen in those with TP53 wild-type advanced/recurrent endometrial cancer who were treated with maintenance selinexor.

T-cell Replete Cord Transplants Give Superior Outcomes in High-risk and Relapsed/refractory Pediatric Myeloid Malignancy

T-cell Replete Cord Transplants Give Superior Outcomes in High-risk and Relapsed/refractory Pediatric Myeloid Malignancy

November 22nd 2023
Article

A recent study published in Nucleus discussed the utility of T-cell replete cord blood transplant in patients with high-risk pediatric acute myeloid leukemia and myelodysplastic syndrome.